Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
Trial record 1 of 5 for:    Translate ACS
Previous Study | Return to List | Next Study

Treatment With Adenosine Diphosphate (ADP) Receptor Inhibitors: Longitudinal Assessment of Treatment Patterns and Events After Acute Coronary Syndrome (TRANSLATE-ACS)

This study has been completed.
Sponsor:
Collaborator:
Daiichi Sankyo Inc.
Information provided by (Responsible Party):
Eli Lilly and Company
ClinicalTrials.gov Identifier:
NCT01088503
First received: March 15, 2010
Last updated: February 18, 2014
Last verified: February 2014

March 15, 2010
February 18, 2014
March 2010
January 2014   (final data collection date for primary outcome measure)
  • Major adverse cardiovascular events (MACE) [ Time Frame: 12 months ] [ Designated as safety issue: No ]
    MACE is defined as a composite of all-cause death, myocardial infarction (MI), stroke, or unplanned coronary revascularization
  • Factors associated with initial ADP receptor inhibitor selection at enrollment and longitudinal patterns of use [ Time Frame: 12 months ] [ Designated as safety issue: No ]
Same as current
Complete list of historical versions of study NCT01088503 on ClinicalTrials.gov Archive Site
  • Bleeding outcomes [ Time Frame: Index hospitalization, 1, 6, 12, 15 months ] [ Designated as safety issue: Yes ]
  • MACE and bleeding outcomes in patients who have no prior history of transient ischemic attack (TIA)/stroke, weigh ≥60 kg, and are age <75 years old [ Time Frame: 12 months ] [ Designated as safety issue: Yes ]
  • MACE [ Time Frame: Index hospitalization, 1, 6, 15 months ] [ Designated as safety issue: No ]
  • Stent thrombosis [ Time Frame: 15 months ] [ Designated as safety issue: No ]
  • Resource use patterns, cumulative total medical costs, and cost effectiveness [ Time Frame: 15 months ] [ Designated as safety issue: No ]
Same as current
Not Provided
Not Provided
 
Treatment With Adenosine Diphosphate (ADP) Receptor Inhibitors: Longitudinal Assessment of Treatment Patterns and Events After Acute Coronary Syndrome
The TRANSLATE-ACS Study: Treatment With ADP Receptor Inhibitors: Longitudinal Assessment of Treatment Patterns and Events After Acute Coronary Syndrome

The TReatment with ADP receptor iNhibitorS: Longitudinal Assessment of Treatment Patterns and Events after Acute Coronary Syndrome (TRANSLATE-ACS) study is a prospective, observational longitudinal study to evaluate the real world effectiveness and use of prasugrel and other ADP receptor inhibitor therapies among myocardial infarction (MI) patients treated with percutaneous coronary intervention (PCI) during the index hospitalization. Patient management and treatment decisions are at the discretion of the care team per routine clinical practice. Approximately 17,000 patients will be enrolled at approximately 350 sites in the United States. Follow-up will be conducted through 15 months in approximately 15,650 patients.

TRANSLATE-ACS will complement the results of both randomized controlled clinical trials and current registries in addressing the real world treatment patterns and clinical outcomes for MI patients managed with PCI and initiated on ADP receptor inhibitor therapy. In addition to determining the effectiveness of prasugrel in comparison to other ADP receptor inhibitors, the study will also determine factors associated with initial ADP receptor inhibitor selection and longitudinal patterns of use, evaluate the safety, and describe and compare resource use and medical costs associated with ADP receptor inhibitors. Additionally, this study will generate a continuum of information from the inpatient to outpatient settings to provide a comprehensive picture of patient treatment and outcomes not currently available for novel ADP receptor inhibitors.

Not Provided
Observational
Observational Model: Cohort
Time Perspective: Prospective
Not Provided
Not Provided
Non-Probability Sample

Patients admitted or already in hospital with acute myocardial infarction (MI) who are treated with percutaneous coronary intervention (PCI) and an ADP receptor inhibitor.

Acute Coronary Syndrome
Drug: ADP receptor inhibitors
Dosage regimen as determined by the treating physician.
ADP receptor inhibitor treatment
Patients admitted for non ST elevation myocardial infarction (NSTEMI) or ST elevation myocardial infarction (STEMI) undergoing percutaneous coronary intervention (PCI) and treated with an ADP receptor inhibitor during the index hospitalization.
Intervention: Drug: ADP receptor inhibitors

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
17350
January 2014
January 2014   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • greater than or equal to 18 years of age
  • diagnosed with NSTEMI or STEMI treated with a PCI during the index hospitalization
  • initiated (or continued) on ADP receptor inhibitor therapy before discharge
  • fully informed and are able to provide written consent for longitudinal follow-up and data collection

Exclusion Criteria:

  • simultaneously participating in a research study that directs choice of either an investigational or approved ADP receptor inhibitor within the first 12 months after MI
Both
18 Years and older
No
Contact information is only displayed when the study is recruiting subjects
United States,   Puerto Rico
 
NCT01088503
12549, H7T-US-B007
Yes
Eli Lilly and Company
Eli Lilly and Company
Daiichi Sankyo Inc.
Study Director: Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours EST) Eli Lilly and Company
Eli Lilly and Company
February 2014

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP